Characterizing Pharmacogenetic Testing Among Children's Hospitals.
Characterizing Pharmacogenetic Testing Among Children's Hospitals.
复制标题
儿童医院药物遗传学检测的特点。
DOI：
10.1111/cts.12931
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Colace SI
中科院分区：
文献类型：
--
作者：
Brown JT;Ramsey LB;Van Driest SL;Aka I;Colace SI
虽然药物遗传学检测在医学亚专业中越来越普遍，但儿科中心的使用和实施范围很广。常规使用药物遗传学在他们的病人护理的大型儿科机构已经公布了他们的做法和经验，但是，最少的数据存在于儿童医院的药物遗传学实施的全方位。这项全国性调查的主要目的是描述儿童医院协会儿童医院药物遗传学检测的可用性、关注点和障碍。从18个机构收到了确认联络人的初步答复。在这18个机构中，收到了14份关于药物遗传学实践的更详细调查的答复（11份完整和3份部分）。大多数受访者来自城市机构（72%），拥有药学博士学位（67%）。在所有受访者中，确定了实施药物遗传学检测的三个主要障碍是检测报销、检测成本和资金。相反，三个最不值得关注的障碍是潜在的遗传歧视，与家庭成员分享结果，以及在认证实验室进行测试的可用性。低使用研究中心对几个障碍的评分显著高于高使用研究中心，包括药物遗传学知识（P = 0.03）、药物遗传学解释（P = 0.04）和基于药物遗传学的治疗变更（P = 0.03）。尽管药物遗传学检测的成本不断降低，但财务障碍是儿科机构尝试临床实施的主要障碍之一。低使用率的网站也可以从教育/宣传中受益，以减少实施的障碍。
Although pharmacogenetic testing is becoming increasingly common across medical subspecialties, a broad range of utilization and implementation exists across pediatric centers. Large pediatric institutions that routinely use pharmacogenetics in their patient care have published their practices and experiences; however, minimal data exist regarding the full spectrum of pharmacogenetic implementation among children’s hospitals. The primary objective of this nationwide survey was to characterize the availability, concerns, and barriers to pharmacogenetic testing in children’s hospitals in the Children’s Hospital Association. Initial responses identifying a contact person were received from 18 institutions. Of those 18 institutions, 14 responses (11 complete and 3 partial) to a more detailed survey regarding pharmacogenetic practices were received. The majority of respondents were from urban institutions (72%) and held a Doctor of Pharmacy degree (67%). Among all respondents, the three primary barriers to implementing pharmacogenetic testing identified were test reimbursement, test cost, and money. Conversely, the three least concerning barriers were potential for genetic discrimination, sharing results with family members, and availability of tests in certified laboratories. Low‐use sites rated several barriers significantly higher than the high‐use sites, including knowledge of pharmacogenetics (P = 0.03), pharmacogenetic interpretations (P = 0.04), and pharmacogenetic‐based changes to therapy (P = 0.03). In spite of decreasing costs of pharmacogenetic testing, financial barriers are one of the main barriers perceived by pediatric institutions attempting clinical implementation. Low‐use sites may also benefit from education/outreach in order to reduce perceived barriers to implementation.
登录
查看更多内容
DOI：
10.1146/annurev-pharmtox-010814-124835
发表时间：
2015
影响因子：
12.5
作者：
Dunnenberger HM;Crews KR;Hoffman JM;Caudle KE;Broeckel U;Howard SC;Hunkler RJ;Klein TE;Evans WE;Relling MV
通讯作者：
Relling MV
影响因子：
64.8
作者：
Relling MV;Evans WE
通讯作者：
Evans WE
影响因子：
6.7
作者：
Ramsey, Laura B.;Prows, Cynthia A.;Glauser, Tracy A.
通讯作者：
Glauser, Tracy A.
影响因子：
6.7
作者：
通讯作者：
--
影响因子：
8
作者：
Crandall, Wallace V.;Margolis, Peter A.;Colletti, Richard B.
通讯作者：
Colletti, Richard B.